Adipose Tissue Inflammation in Breast Cancer Survivors: Effects of a 16-week Combined Aerobic and Resistance Exercise Training Intervention
Overview
Authors
Affiliations
Purpose: Obesity is a leading modifiable contributor to breast cancer mortality due to its association with increased recurrence and decreased overall survival rate. Obesity stimulates cancer progression through chronic, low-grade inflammation in white adipose tissue, leading to accumulation of adipose tissue macrophages (ATMs), in particular, the pro-inflammatory M1 phenotype macrophage. Exercise has been shown to reduce M1 ATMs and increase the more anti-inflammatory M2 ATMs in obese adults. The purpose of this study was to determine whether a 16-week exercise intervention would positively alter ATM phenotype in obese postmenopausal breast cancer survivors.
Methods: Twenty obese postmenopausal breast cancer survivors were randomized to a 16-week aerobic and resistance exercise (EX) intervention or delayed intervention control (CON). The EX group participated in 16 weeks of supervised exercise sessions 3 times/week. Participants provided fasting blood, dual-energy X-ray absorptiometry (DXA), and superficial subcutaneous abdominal adipose tissue biopsies at baseline and following the 16-week study period.
Results: EX participants experienced significant improvements in body composition, cardiometabolic biomarkers, and systemic inflammation (all p < 0.03 vs. CON). Adipose tissue from EX participants showed a significant decrease in ATM M1 (p < 0.001), an increase in ATM M2 (p < 0.001), increased adipose tissue secretion of anti-inflammatory cytokines such as adiponectin, and decreased secretion of the pro-inflammatory cytokines IL-6 and TNF- α (all p < 0.055).
Conclusions: A 16-week aerobic and resistance exercise intervention attenuates adipose tissue inflammation in obese postmenopausal breast cancer survivors. Future large randomized trials are warranted to investigate the impact of exercise-induced reductions in adipose tissue inflammation and breast cancer recurrence.
Lee J, Hwang Y J Cancer Surviv. 2025; .
PMID: 40056311 DOI: 10.1007/s11764-025-01772-x.
Gu H, Zhu T, Ding J, Yang Z, Lu Y, Guo G Front Oncol. 2025; 15:1402300.
PMID: 39980560 PMC: 11839753. DOI: 10.3389/fonc.2025.1402300.
Gu J, Zhang H, Qian K, Ye X, Wu G Int J Womens Health. 2024; 16:2157-2171.
PMID: 39713093 PMC: 11662632. DOI: 10.2147/IJWH.S496718.
Head and Neck Cancer (HNC) Prehabilitation: Advantages and Limitations.
Demurtas S, Cena H, Benazzo M, Gabanelli P, Porcelli S, Preda L J Clin Med. 2024; 13(20).
PMID: 39458125 PMC: 11509296. DOI: 10.3390/jcm13206176.
Ahn C, Zhang T, Yang G, Rode T, Varshney P, Ghayur S Nat Metab. 2024; 6(9):1819-1836.
PMID: 39256590 DOI: 10.1038/s42255-024-01103-x.